At least two isoforms of TET2 are known to exist, this antibody will detect both isoforms.
Aufreinigung
TET2 Antibody is affinity chromatography purified via peptide column.
Immunogen
TET2 antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human TET2. The immunogen is located within amino acids 20 - 70 of TET2.
TET2
Reaktivität: Human
WB, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
TET2 antibody can be used for detection of TET2 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
TET2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
TET2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TET2
(Tet Methylcytosine Dioxygenase 2 (TET2))
Andere Bezeichnung
TET2
Hintergrund
TET2 Antibody: TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14 % of patients with JAK2V617F-positive myeloproliferative neoplasms, and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.